<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and Burkitt-like <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) are clinically and biologically aggressive B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Brief-duration, high intensity multidrug regimens with central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) prophylaxis have proven to be effective, with published series of adult patients documenting complete response (CR) rates of 80 to 100 percent and 2-year event-free survival (EFS) rates ranging from 60 to 90 percent </plain></SENT>
<SENT sid="2" pm="."><plain>Based upon the known sensitivity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> to <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and favorable results reported from the Dana Farber <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center using high-dose CHOP in diffuse aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, we tested a regimen designed to maximize the administered dose of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> while eliminating other agents commonly used in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> protocols </plain></SENT>
<SENT sid="3" pm="."><plain>Eleven patients with Burkitt or Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with 4 cycles of a 5-drug regimen, called high-dose CHOP, which contains a <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> dose of 4 gm/m2 with each cycle </plain></SENT>
<SENT sid="4" pm="."><plain>Intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and midcycle high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were added as <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>Ten patients achieved a complete response (91 percent) and with a median follow up of 38 months, the 3-year EFS is 64 percent and the 3-year overall survival (OS) is 72 percent </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients recurred after the achievement of a CR </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment-related toxicities included <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, neutropenic <z:hpo ids='HP_0001945'>fevers</z:hpo>/<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, and <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> requiring hemodialysis in 2 patients </plain></SENT>
<SENT sid="8" pm="."><plain>There were no treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> and none of the patients had to discontinue therapy secondary to toxicity </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, the high-dose CHOP with midcycle <z:chebi fb="0" ids="44185">methotrexate</z:chebi> regimen produces response rates and EFS rates comparable to other regimens, with an acceptable toxicity profile </plain></SENT>
<SENT sid="10" pm="."><plain>Utilization of high dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> may eliminate the need for several other agents in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> regimens </plain></SENT>
</text></document>